When comparing the AMPA reactivity anti-chimeric enolase peptides in RA patients, we observed significant differences between antibody levels in anti-fibrin/enolase or enolase/filaggrin and anti-vimentin/enolase peptides, while the differences in antibody levels were not significant between fibrin/enolase and enolase/filaggrin peptides (Figure 3). The gene discussed is VIM; the disease is rheumatoid arthritis.